New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Molecular tracer, seen with PET scan, shows concentrations of abnormal proteins

Molecular tracer, seen with PET scan, shows concentrations of abnormal proteins

by University of California, Los AngelesResearchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encep
Neurology April 01,2024
Molecular tracer, seen with PET scan, shows concentrations of abnormal proteins

Molecular tracer, seen with PET scan, shows concentrations of abnormal proteins

by University of California, Los AngelesResearchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encep
Neurology April 01,2024
PET tracer gauges effectiveness of promising Alzheimer's treatment

PET tracer gauges effectiveness of promising Alzheimer's treatment

by Society of Nuclear Medicine and Molecular ImagingPET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observ
Neurology April 01,2024
PET tracer gauges effectiveness of promising Alzheimer's treatment

PET tracer gauges effectiveness of promising Alzheimer's treatment

by Society of Nuclear Medicine and Molecular ImagingPET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observ
Neurology April 01,2024
Successful Phase 2 clinical trial for neflamapimod in mild-to-moderate Lewy body dementia

Successful Phase 2 clinical trial for neflamapimod in mild-to-moderate Lewy body dementia

by University of North Carolina at Chapel Hill School of MedicineCredit: CC0 Public DomainEIP Pharma announced on October 6 that a phase 2 study in patients with mild-to-moderate Lewy body dement
Neurology April 01,2024
Successful Phase 2 clinical trial for neflamapimod in mild-to-moderate Lewy body dementia

Successful Phase 2 clinical trial for neflamapimod in mild-to-moderate Lewy body dementia

by University of North Carolina at Chapel Hill School of MedicineCredit: CC0 Public DomainEIP Pharma announced on October 6 that a phase 2 study in patients with mild-to-moderate Lewy body dement
Neurology April 01,2024
PET points to tau protein as leading culprit in Alzheimer's

PET points to tau protein as leading culprit in Alzheimer's

by Society of Nuclear MedicineTopographical correspondence of tau- but not amyloid-pathology with neuronal dysfunction in Alzheimer's disease. Right lateral surface of projected z-score image
Neurology April 01,2024
PET points to tau protein as leading culprit in Alzheimer's

PET points to tau protein as leading culprit in Alzheimer's

by Society of Nuclear MedicineTopographical correspondence of tau- but not amyloid-pathology with neuronal dysfunction in Alzheimer's disease. Right lateral surface of projected z-score image
Neurology April 01,2024
Reelin reverts the main pathological processes related to Alzheimer's and other tauopathy

Reelin reverts the main pathological processes related to Alzheimer's and other tauopathy

by University of BarcelonaImage of a primary neuronal cell culture with detection of MAP2 dendritic marker (red) and Neurofilament axon marker (green). Credit: University of BarcelonaPromoting th
Neurology April 01,2024
Reelin reverts the main pathological processes related to Alzheimer's and other tauopathy

Reelin reverts the main pathological processes related to Alzheimer's and other tauopathy

by University of BarcelonaImage of a primary neuronal cell culture with detection of MAP2 dendritic marker (red) and Neurofilament axon marker (green). Credit: University of BarcelonaPromoting th
Neurology April 01,2024
PET scans for Alzheimer's could bring benefit to more patients

PET scans for Alzheimer's could bring benefit to more patients

by Ryan O'hare,Imperial College LondonPET scans can spot amyloid in the brain (pictured). Credit: Imperial College LondonAn imaging tool honed to spot rogue proteins in the brain could benef
Neurology April 01,2024
PET scans for Alzheimer's could bring benefit to more patients

PET scans for Alzheimer's could bring benefit to more patients

by Ryan O'hare,Imperial College LondonPET scans can spot amyloid in the brain (pictured). Credit: Imperial College LondonAn imaging tool honed to spot rogue proteins in the brain could benef
Neurology April 01,2024
Promising Alzheimer's research takes a step forward

Promising Alzheimer's research takes a step forward

by University of LiverpoolCredit: University of LiverpoolScientists from the University of Liverpool and Victoria University of Wellington have been awarded over £478K to advance a potential trea
Neurology April 01,2024
Promising Alzheimer's research takes a step forward

Promising Alzheimer's research takes a step forward

by University of LiverpoolCredit: University of LiverpoolScientists from the University of Liverpool and Victoria University of Wellington have been awarded over £478K to advance a potential trea
Neurology April 01,2024
On Nutrition: Food for thoughts

On Nutrition: Food for thoughts

by Barbara IntermillCredit: Unsplash/CC0 Public DomainI forgot that June was Brain Health Awareness Month. And then I stumbled over several interesting research articles that say it's never to lat
Neurology April 01,2024
On Nutrition: Food for thoughts

On Nutrition: Food for thoughts

by Barbara IntermillCredit: Unsplash/CC0 Public DomainI forgot that June was Brain Health Awareness Month. And then I stumbled over several interesting research articles that say it's never to lat
Neurology April 01,2024
MS treatment that 'resets' immune system may halt disease progression for at least five years

MS treatment that 'resets' immune system may halt disease progression for at least five years

by Imperial College LondonDemyelination by MS. The CD68 colored tissue shows several macrophages in the area of the lesion. Original scale 1:100. Credit:CC BY-SA 3.0Marvin 101/Wikiped
Neurology April 01,2024
MS treatment that 'resets' immune system may halt disease progression for at least five years

MS treatment that 'resets' immune system may halt disease progression for at least five years

by Imperial College LondonDemyelination by MS. The CD68 colored tissue shows several macrophages in the area of the lesion. Original scale 1:100. Credit:CC BY-SA 3.0Marvin 101/Wikiped
Neurology April 01,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com